DE69934179D1 - Zusammensetzung enthaltend, ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure, zur Verwendung in der Immunisierung - Google Patents

Zusammensetzung enthaltend, ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure, zur Verwendung in der Immunisierung

Info

Publication number
DE69934179D1
DE69934179D1 DE69934179T DE69934179T DE69934179D1 DE 69934179 D1 DE69934179 D1 DE 69934179D1 DE 69934179 T DE69934179 T DE 69934179T DE 69934179 T DE69934179 T DE 69934179T DE 69934179 D1 DE69934179 D1 DE 69934179D1
Authority
DE
Germany
Prior art keywords
antigen
amino acid
immunization
composition containing
water soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934179T
Other languages
English (en)
Other versions
DE69934179T2 (de
Inventor
Alan Wheeler
Anthony Berry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergy Therapeutics UK Ltd
Original Assignee
Allergy Therapeutics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergy Therapeutics UK Ltd filed Critical Allergy Therapeutics UK Ltd
Publication of DE69934179D1 publication Critical patent/DE69934179D1/de
Application granted granted Critical
Publication of DE69934179T2 publication Critical patent/DE69934179T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69934179T 1998-09-21 1999-09-17 Zusammensetzung enthaltend ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure zur Verwendung in der Immunisierung Expired - Lifetime DE69934179T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9820525 1998-09-21
GBGB9820525.5A GB9820525D0 (en) 1998-09-21 1998-09-21 Formulation

Publications (2)

Publication Number Publication Date
DE69934179D1 true DE69934179D1 (de) 2007-01-11
DE69934179T2 DE69934179T2 (de) 2007-04-19

Family

ID=10839197

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934179T Expired - Lifetime DE69934179T2 (de) 1998-09-21 1999-09-17 Zusammensetzung enthaltend ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure zur Verwendung in der Immunisierung

Country Status (13)

Country Link
US (2) US6440426B1 (de)
EP (1) EP0988862B1 (de)
JP (2) JP4743928B2 (de)
KR (1) KR100642877B1 (de)
AT (1) ATE346610T1 (de)
AU (1) AU766251B2 (de)
CA (1) CA2282779C (de)
DE (1) DE69934179T2 (de)
DK (1) DK0988862T3 (de)
ES (1) ES2277413T3 (de)
GB (2) GB9820525D0 (de)
NZ (1) NZ337885A (de)
PT (1) PT988862E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2002013855A2 (en) * 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) * 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
DK1324776T4 (en) * 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ATE363522T1 (de) * 2001-01-30 2007-06-15 Schwan Stabilo Schwanhaeusser Markierungsflüssigkeit
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8333976B2 (en) * 2003-08-28 2012-12-18 Sandor Sipka Processes for inhibiting development of allergic disease
CN101123982B (zh) * 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
KR20110128333A (ko) * 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CA2923030A1 (en) 2013-10-03 2015-04-09 Nitto Denko Corporation Injectable vaccine composition

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) * 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (de) 1978-12-22 1996-04-03 Biogen, Inc. Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
FR2621916B1 (fr) * 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
KR950700083A (ko) 1992-03-03 1995-01-16 스즈키 다다시 경구용 백신(oral vaccine)
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CN1087176C (zh) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AU676340B2 (en) 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
AU7482694A (en) 1993-08-27 1995-03-21 Enteric Research Laboratories, Inc. (campylobacter jejuni) antigens, and methods for their production and use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
AU4977896A (en) 1995-02-17 1996-09-04 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CN1326564C (zh) 1997-04-01 2007-07-18 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
WO1998058956A2 (en) 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1029053A1 (de) 1997-11-10 2000-08-23 Statens Seruminstitut Nukleinsäurefragmente und polypeptide von mycobacterium tuberculosis
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
AU4510299A (en) * 1998-06-12 2000-01-05 Smithkline Beecham Biologicals (Sa) Recombinant production of toxoplasma sag1 antigen
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
DE69942774D1 (de) 1999-02-26 2010-10-28 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
IL145786A0 (en) 1999-04-23 2002-07-25 M & E Biotech As Method for down-regulating il5 activity
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9924529D0 (en) 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
JP2010265330A (ja) 2010-11-25
GB2341801A (en) 2000-03-29
EP0988862A3 (de) 2001-06-20
GB9820525D0 (en) 1998-11-11
NZ337885A (en) 2001-01-26
ES2277413T3 (es) 2007-07-01
KR100642877B1 (ko) 2006-11-13
ATE346610T1 (de) 2006-12-15
CA2282779A1 (en) 2000-03-21
US20030007977A1 (en) 2003-01-09
DE69934179T2 (de) 2007-04-19
GB9922121D0 (en) 1999-11-17
GB2341801B (en) 2003-10-29
JP4743928B2 (ja) 2011-08-10
EP0988862A2 (de) 2000-03-29
AU4877799A (en) 2000-06-08
DK0988862T3 (da) 2006-12-27
US6440426B1 (en) 2002-08-27
KR20000023273A (ko) 2000-04-25
EP0988862B1 (de) 2006-11-29
JP2000103745A (ja) 2000-04-11
AU766251B2 (en) 2003-10-09
CA2282779C (en) 2011-02-01
PT988862E (pt) 2007-01-31
US7815920B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
DE69934179D1 (de) Zusammensetzung enthaltend, ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure, zur Verwendung in der Immunisierung
DE59008475D1 (de) Verwendung eines schwer löslichen Salzes einer Heteropolysäure zur Bestimmung eines Analyts, entsprechendes Bestimmungsverfahren sowie hierfür geeignetes Mittel.
NO864556L (no) Fremgangsmaate ved fremstilling av insulinpreparat.
DE69033067T2 (de) 4,7-dichlorfluoreszein-farbstoffe als molekulare sonden
DE60029589D1 (de) Verfahren zur herstellung von azithromycin
ATE288276T1 (de) Zusammensetzung zur gewichtserhöhung von vieh, die ein ionophore und selenium enthält
NO903757L (no) Kitin.kitosan-oligomer med 2,5-anhydromannitol endegruppeeller 2,5-anhydromannose endegruppe og fremgangsmaate til fremstilling derav.
ATE177785T1 (de) Mutante des respiratory-syncytial-virus (rs- virus) und eine eine solche mutante enthaltende pharmazeutische zusammensetzung
DK87190A (da) Fremgangsmaade til at regulere plantevaekst under anvendelse af svovlholdige organiske syrer
DE69018755D1 (de) Verfahren zur Herstellung von 3-(L-Pyroglutamyl)-L-thiazolidin-4-carbonsäure-Derivaten.
DK88087A (da) Tricyklisk 5-(3-chlor-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo-(c,f)-(1,2)-thiazepin-11-yl)-amino-pentansyrederivat, fremgangsmaade til fremstilling deraf og farmaceutiske midler indeholdende dem
ATE92469T1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
DK44688A (da) Beta-alkylmelatoniner, fremgangsmaade til fremstilling deraf og mellemprodukter til brug ved fremgangsmaaden
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
DE3852105T2 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
ATE135703T1 (de) Substituierte 2-imidazoline und verfahren zur herstellung sowie deren verwendung
ES2081878T3 (es) Procedimiento para la preparacion discontinua de l-carnitina por via microbiologica.
DE3770287D1 (de) Neue n-glycosylamidderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
DE59003230D1 (de) Verfahren zur Herstellung von 2,4- bzw. 2,6-Dihalogen-anilin.
ES2061550T3 (es) Vinilcefalosporinas substituidas, procedimiento para su preparacion y su uso como medicamento.
BR9403572A (pt) Composto, processo para sua preparação e formulação farmacêutica
DE69103388D1 (de) Thexyl-(C1-C4)alkyl-dialkoxysilane, Verfahren zur Herstellung und deren Verwendung.
DE3881471D1 (de) Oxethylsulfonyl-nitro- bzw. -amino-benzoesaeuren und verfahren zu ihrer herstellung.
DE59104769D1 (de) Verfahren zur Herstellung von 4,4'-Bis(4-aminophenoxy)diphenylsulfon.
DK1165087T3 (da) In vivo-farvestof og anvendelsesmetode til identificering af dysplastisk væv

Legal Events

Date Code Title Description
8364 No opposition during term of opposition